Hardy Diagnostics entered into an exclusive partnership with the Swedish-based company Gradientech to distribute its FDA-classified breakthrough device, the QuickMIC.
The QuickMIC results contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions.
The QuickMIC system is currently undergoing 510(k) clinical studies at two well-renowned hospitals in the United States. The QuickMIC system is already available and in use at many hospitals in Europe.
